CervoMed Inc Sustainability Reports
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule brain penetrant being developed for the treatment of dementia with Lewy bodies.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300I3DV7F8OXPNA12
FIGI: BBG001SD4Z42
1 reports from 2024 to 2024
